Keros Therapeutics, Inc. KROS
Set alert
10.76 USD -0.28 -2.54%
At close · Nov 2
10.76 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
10.53 Day range 11.39
9.69 52-week range 22.55
- YTD
- -47.15%
- 1 year
- -29.30%
- Open
- 11.12
- Prev close
- 11.04
- Mkt cap
- 213.34M
- Vol
- 139.24K
- Avg vol
- 188.77K
- EPS
- -3.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.53
- High
- 11.39
- Forward P/E
- -3.00
- Beta
- 1.24
- Short ratio
- 5.28
- Inst. own
- 100.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 55.00
- 200-d avg
- 53.85
- 1y target
- 43.55
Held by funds
71 US ETFs and mutual funds hold KROS · largest positions
Ownership
Held by insiders 5.43%
Held by institutions 100.86%
Float held by institutions 106.66%
Institutions 244
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.09% | 4,899,134 | 83.87M | Sep 29, 2024 |
| Blackrock Inc. | 6.50% | 2,632,608 | 45.07M | Sep 29, 2024 |
| Alkeon Capital Management LLC | 4.68% | 1,897,601 | 32.49M | Sep 29, 2024 |
| Vanguard Group Inc | 4.58% | 1,856,418 | 31.78M | Sep 29, 2024 |
| Darwin Global Management, Ltd. | 3.76% | 1,523,732 | 26.09M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.74% | 1,514,505 | 25.93M | Sep 29, 2024 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 961,347 | 16.46M | Sep 29, 2024 |
| ACAP Strategic Fund | 2.31% | 933,991 | 15.99M | Sep 29, 2024 |
| Price (T.Rowe) New Horizons Fund | 2.17% | 877,880 | 15.03M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 756,550 | 12.95M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.63% | 661,229 | 11.32M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.60% | 650,000 | 11.13M | Oct 30, 2024 |
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GORDON CARL L | Director | Sale | Aug 12, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 12, 2024 | 0 |
| REGNANTE KEITH C | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 2, 2023 | 0 |
| SEEHRA JASBIR | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 6, 2023 | 252,856 |